Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học: " Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study | Journal of Neuroinflammation BioMed Central Open Access Saliva soluble HLA as a potential marker of response to interferon-p1a in multiple sclerosis A preliminary study Alireza Minagar 1 Irena Adamashvili1 Roger E Kelley1 Eduardo Gonzalez-Toledo2 Jerry McLarty3 and Stacy J Smith1 Address Department of Neurology LSU Health Sciences Center Shreveport Louisiana USA 2Department of Radiology LSU Health Sciences Center Shreveport Louisiana USA and 3Department of Internal Medicine LSU Health Sciences Center Shreveport Louisiana USA Email Alireza Minagar - aminag@lsuhsc.edu Irena Adamashvili - IAdama@lsuhsc.edu Roger E Kelley - rkelly@lsuhsc.edu Eduardo Gonzalez-Toledo - egonz1@lsuhsc.edu Jerry McLarty - jmclar@lsuhsc.edu Stacy J Smith - ssmi12@lsuhsc.edu Corresponding author Published I July 2007 Received 8 February 2007 Journal of Neuroinflammation 2007 4 16 doi 10.1186 1742-2094-4-16 Accepted 1 July 2007 This article is available from http www.jneuroinflammation.eom content 4 I I6 2007 Minagar et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Objective Potential surrogate markers of disease activity including response to therapy are particularly important in a neurological disorder such as multiple sclerosis MS which often has a fluctuating course. Based upon previous studies in our laboratory we hypothesized that measurement of soluble HLA sHLA molecules class II in saliva of MS patients can serve as marker of therapeutic response to high dose interferon beta-Ia. Methods We measured the expression patterns of sHLA-II in saliva in I7 patients with relapsing remitting MS and compared the results to clinical course and brain MRI. For comparison purposes we also assayed the saliva sHLA-II levels in 53 normal control .